Prestige Consumer Healthcare’s (PBH) Buy Rating Reaffirmed at DA Davidson

Prestige Consumer Healthcare (NYSE:PBH)‘s stock had its “buy” rating reissued by equities researchers at DA Davidson in a research report issued to clients and investors on Friday, Benzinga reports. They presently have a $93.00 target price on the stock. DA Davidson’s price objective suggests a potential upside of 40.38% from the stock’s previous close.

Several other brokerages have also recently commented on PBH. StockNews.com cut Prestige Consumer Healthcare from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, May 21st. Canaccord Genuity Group restated a “buy” rating and issued a $80.00 price objective on shares of Prestige Consumer Healthcare in a research note on Tuesday, May 21st. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $98.25.

Prestige Consumer Healthcare Trading Down 0.9 %

Prestige Consumer Healthcare stock traded down $0.59 during midday trading on Friday, reaching $66.25. The stock had a trading volume of 274,252 shares, compared to its average volume of 253,038. The firm’s fifty day simple moving average is $68.20 and its two-hundred day simple moving average is $68.56. The firm has a market cap of $3.29 billion, a price-to-earnings ratio of 15.89, a PEG ratio of 1.93 and a beta of 0.49. Prestige Consumer Healthcare has a twelve month low of $56.34 and a twelve month high of $75.31. The company has a debt-to-equity ratio of 0.68, a current ratio of 3.20 and a quick ratio of 2.02.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings results on Thursday, August 8th. The company reported $0.90 earnings per share for the quarter, beating the consensus estimate of $0.86 by $0.04. The firm had revenue of $267.10 million for the quarter, compared to analyst estimates of $260.54 million. Prestige Consumer Healthcare had a return on equity of 13.48% and a net margin of 18.60%. Prestige Consumer Healthcare’s quarterly revenue was down 4.4% on a year-over-year basis. During the same period in the previous year, the firm earned $1.06 earnings per share. Equities analysts anticipate that Prestige Consumer Healthcare will post 4.42 EPS for the current fiscal year.

Institutional Investors Weigh In On Prestige Consumer Healthcare

A number of institutional investors have recently added to or reduced their stakes in the company. Covestor Ltd boosted its position in shares of Prestige Consumer Healthcare by 21.6% during the 1st quarter. Covestor Ltd now owns 834 shares of the company’s stock valued at $61,000 after acquiring an additional 148 shares in the last quarter. Miller Howard Investments Inc. NY raised its holdings in shares of Prestige Consumer Healthcare by 2.2% in the 2nd quarter. Miller Howard Investments Inc. NY now owns 7,762 shares of the company’s stock worth $534,000 after buying an additional 165 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in shares of Prestige Consumer Healthcare by 80.6% during the 1st quarter. EverSource Wealth Advisors LLC now owns 466 shares of the company’s stock worth $33,000 after buying an additional 208 shares during the period. Parallel Advisors LLC raised its stake in Prestige Consumer Healthcare by 42.5% during the fourth quarter. Parallel Advisors LLC now owns 714 shares of the company’s stock worth $44,000 after acquiring an additional 213 shares in the last quarter. Finally, QRG Capital Management Inc. lifted its holdings in shares of Prestige Consumer Healthcare by 4.7% during the second quarter. QRG Capital Management Inc. now owns 5,397 shares of the company’s stock valued at $372,000 after acquiring an additional 242 shares during the period. 99.95% of the stock is owned by institutional investors and hedge funds.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.